Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
39.99 USD | +3.95% | +78.37% | +55.34% |
May. 31 | Citigroup Downgrades Calliditas Therapeutics to Neutral From Buy, Price Target at $39 | MT |
May. 31 | Calliditas Partner Secures European Panel Backing for Rare Kidney Disease Treatment | MT |
- Stock Market
- Equities
- CALTX Stock
- CALT Stock
- News Calliditas Therapeutics AB